Drug intelligence / Profile preview

Japanese encephalitis inactivated vaccine

Development stage
Approved
Lead developer
Valneva
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Japanese encephalitis inactivated vaccine is a biologic vaccine used to prevent infection caused by the Japanese encephalitis virus (JEV), a mosquito-borne flavivirus that can cause severe neurological disease. The inactivated vaccines are produced using Vero cell culture technology and work by stimulating the immune system to produce protective antibodies against JEV. The primary indication is for individuals traveling to or living in areas where Japanese encephalitis is endemic, as well as for military personnel and laboratory workers at risk of exposure. The most widely used brands include IXIARO (manufactured by Valneva) and JEspect. These vaccines are administered intramuscularly, typically as a two-dose series spaced 28 days apart. Inactivated vaccines are preferred for immunocompromised individuals and pregnant women due to their safety profile[1][2][3][4][7][8].

Brand names
IXIAROJEspect
Other names
Japanese encephalitis Vero cell vaccineJE-VCJapanese encephalitis virus vaccine, inactivated, adsorbed
02

Targets

NSP3 (SARS-CoV-2 non-structural protein 3)E (Tick-borne encephalitis virus envelope protein)pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on Japanese encephalitis inactivated vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Japanese encephalitis inactivated vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call